Jak2 Inhibitors are the solution for Myelo Proliferative Disorders

The recent discovery of JAK2 –activating mutations as a casual event in the majority of patients with Philadelphia chromosome negative (ph-)myeloproliferative disorders (MPDs) prompted many pharmaceutical companies to develop JAK2- selective inhibitors for the treatment of MPD’S . JAK2 inhibitors effectively reduce JAK2 driver phosphorylation of signal-transducer and activator of transcription 5,and cell proliferation and cell survival in JAK 2 activated cells in vitro and invivo. The results of ongoing clinical trials will allow further evaluation of clinical benefits and safety of these compounds. In this review the authors summarize the status of JAK2 inhibitors in development and discuss their benefits and challenges.

Author(s): Siva jyothi Buggana, Swetha Padigela,Safuara Ayesha mujeeb, Priyanka kuthadi

Abstract | Full-Text | PDF

Share this  Facebook  Twitter  LinkedIn  Google+
30+ Million Readerbase
Recommended Conferences
Flyer image
Abstracted/Indexed in
  • Google Scholar
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • Scimago
  • Directory of Research Journal Indexing (DRJI)
  • WorldCat
  • Publons
  • MIAR
  • ResearchGate
  • University Grants Commission
  • Secret Search Engine Labs


tempobet giriş

tempobet giriş

tipobet süpertotobet yeni adres süperbahis 747 güvenilir bahis siteleri telefonda sex sohbet